These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 5381315)

  • 1. [Testing the activity of anti-foot-and-mouth disease aluminum hydroxide formol vaccine on guinea pigs].
    Kuleshova LA; Kozlovskiĭ GA; Sorvachev EV; Murashkin VI
    Veterinariia; 1969 May; 5():25-7. PubMed ID: 5381315
    [No Abstract]   [Full Text] [Related]  

  • 2. [On the immunizing properties of GOAL-formol vaccine and GNKI dry virus vaccine against foot-and-mouth disease].
    Lazarev PS; Amelin IP; Zaslonov MS
    Veterinariia; 1966 Sep; 43(9):30-1. PubMed ID: 6011469
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines.
    Hyslop NS; Morrow AW
    Res Vet Sci; 1969 Mar; 10(2):109-20. PubMed ID: 5818030
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunological studies with cell cultured aluminium hydroxide gel adsorbed formalin inactivated foot and mouth disease type Asia I monovalent vaccine.
    Negi BS; Kumar S
    Indian Vet J; 1970 Jul; 47(7):555-61. PubMed ID: 4318813
    [No Abstract]   [Full Text] [Related]  

  • 5. [On the production of monovalent foot-and-mouth disease vaccine concentrate from tissue culture virus type O].
    Mitev G; Wassilewa L; Tekerlekov P
    Arch Exp Veterinarmed; 1966 Mar; 20(1):85-90. PubMed ID: 4293436
    [No Abstract]   [Full Text] [Related]  

  • 6. [Study of the immunity in sheep inoculated with aluminum hydroxide formolized vaccine against foot-and-mouth disease].
    Irza LA
    Veterinariia; 1973 Sep; 9():38-40. PubMed ID: 4783613
    [No Abstract]   [Full Text] [Related]  

  • 7. [Foot-and-mouth virus component responsible for immunogenesis].
    Salazhov EL; Ivanov VS
    Veterinariia; 1970 Sep; 9():38-40. PubMed ID: 4323895
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effectiveness of anti-foot-and-mouth disease GOA-formol vaccine with saponin].
    Antoniuk VP; Kruglikov BA; Barbashov VP; Bashkatov SF; Chernyshova GT
    Veterinariia; 1972 Sep; 9():61-2. PubMed ID: 4667544
    [No Abstract]   [Full Text] [Related]  

  • 9. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus.
    Zheng M; Jin N; Zhang H; Jin M; Lu H; Ma M; Li C; Yin G; Wang R; Liu Q
    J Virol Methods; 2006 Sep; 136(1-2):230-7. PubMed ID: 16780963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of formol in foot-and-mouth disease vaccines by the iodometric method].
    Strobbe R
    Bull Off Int Epizoot; 1965; 63(5):883-90. PubMed ID: 5892237
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs.
    Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P
    Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
    Yao Q; Qian P; Huang Q; Cao Y; Chen H
    J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant fusion protein and DNA vaccines against foot-and-mouth disease virus type Asia 1 infection in guinea pigs.
    Zhang Q; Zhu MW; Yang YQ; Shao M; Zhang ZY; Lan HY; Yan WY; Wu JJ; Zheng ZX
    Acta Virol; 2003; 47(4):237-43. PubMed ID: 15068379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [On testing the efficiency of foot-and-mouth disease hyperimmune serum in guinea pigs by injecting myotropic foot-and-mouth disease virus strains].
    Bengelsdorff HJ
    Zentralbl Veterinarmed B; 1965 Jul; 12(4):340-50. PubMed ID: 4283976
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparative testing of methods for the control of foot-and-mouth disease vaccines on guinea pigs].
    Tekerlekov P; Mitev G; Nikolova E; Gergov P
    Vet Med Nauki; 1975; 12(1):25-9. PubMed ID: 1209994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenic properties of an experimental vaccine against foot-and-mouth disease].
    Siusiukin AA; Kravets IK; Tsvetkova NE; Pavlov VG
    Veterinariia; 1971 May; 5():40-2. PubMed ID: 5158658
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine.
    Du Y; Li Y; He H; Qi J; Jiang W; Wang X; Tang B; Cao J; Wang X; Jiang P
    J Virol Methods; 2008 Apr; 149(1):144-52. PubMed ID: 18294705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a recombinant fusion protein of tandem repeat epitopes of foot-and-mouth disease virus type Asia 1 for guinea pigs.
    Zhang Q; Yang YQ; Zhang ZY; Li L; Yan WY; Jiang WJ; Xin AG; Lei CX; Zheng ZX
    Acta Virol; 2002; 46(1):1-9. PubMed ID: 12199204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant P1 polyprotein expressed in Pichia pastoris.
    Balamurugan V; Renji R; Venkatesh G; Reddy GR; Nair SP; Ganesh K; Suryanarayana VV
    Arch Virol; 2005 May; 150(5):967-79. PubMed ID: 15662485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease.
    Dunn CS; Samuel AR; Pullen LA; Anderson J
    Virology; 1998 Jul; 247(1):51-61. PubMed ID: 9683571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.